Toyoda Gosei Invests in ThinkCyte, a Startup Developing Devices for the Early Detection of Leukemia and Other Diseases
28 Nov 2023
Cell Therapy
KIYOSU, Japan--(BUSINESS WIRE)-- Toyoda Gosei Co., Ltd. (TOKYO:7282) has invested* in ThinkCyte K.K., whose technologies are used for a broad spectrum of applications, including the early detection of leukemia and other diseases, with the aim of solving social issues in the healthcare field.
This press release features multimedia. View the full release here:
Cell sorter developed by ThinkCyte (Graphic: Business Wire)
ThinkCyte is a startup developing and commercializing cell analysis and sorting technology platform using AI-based cell image analysis. The company’s technology to analyze individual cells and sort them will enable faster and more accurate diagnoses than conventional methods. Its technology also holds future promise for use in drug discovery.
Toyoda Gosei has been focusing efforts on product development and collaboration with companies in the field of preventive medicine, to help increase life expectancy. Using its technologies in the molding of plastic materials and mold processing, Toyoda Gosei will cultivate business in the healthcare field through its contributions to the commercialization of devices being developed by ThinkCyte.
* Investment made in October 2023, through Toyoda Gosei’s Corporate Venture Capital Dept., an internal organization dedicated to these investments.
Outline of ThinkCyte
Name
ThinkCyte K.K.
Location
7-3-1 Hongo, Bunkyo, Tokyo, Japan
CEO
Waichiro Katsuda
Established
February 2016
Capital
JPY 1.207 billion (as of August 2023)
View source version on businesswire.com:
Contacts
Toyoda Gosei Co., Ltd.
Contact: Public Relations
inquiry@mlist.toyoda-gosei.co.jp
Source: Toyoda Gosei Co., Ltd.
Smart Multimedia Gallery
Photo
Cell sorter developed by ThinkCyte (Graphic: Business Wire)
Logo
View this news release and multimedia online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.